Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma

Yan,Fei; Zheng,Yi; Huang,Laiqiang

doi:10.3892/ol.2012.987

Adenovirus-mediated combined anti-angiogenic and pro-apoptotic gene therapy enhances antitumor efficacy in hepatocellular carcinoma

Authors:
- Fei Yan
- Yi Zheng
- Laiqiang Huang
View Affiliations

Affiliations: The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech and Bio-Medicine and Division of Life Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, P.R. China
Published online on: October 23, 2012 https://doi.org/10.3892/ol.2012.987
Pages: 348-354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A previous study reported that combinatorial human endostatin and soluble tumor necrosis factor (TNF)‑related apoptosis-inducing ligand (sTRAIL) gene transfer suppresses human hepatocellular carcinoma (HCC) growth and angiogenesis using the pVAX1 plasmid vector. The current study investigated the antitumor efficacy in HCC through adenovirus-mediated combination gene therapy. Human endostatin and sTRAIL (114 to 281 AA) genes were amplified and cloned into the Adeno-X expression vector. The recombinant adenoviruses (Ad-E and Ad-T) were packaged, amplified in the HEK 293 cells and used to infect human umbilical vein endothelial cells (HUVECs) and HepG2 cells, respectively. The results revealed that a significant cell growth inhibition was observed in the two types of cells using a cell viability assay. Intratumoral administration with Ad-E and Ad-T revealed a significant enhanced regression of the tumors compared with treatment with either recombinant adenovirus alone. Histology and immunohistochemistry examination further indicated that the inhibition of tumor growth appeared to result from increased apoptosis and reduced angiogenesis in tumor xenografts. In conclusion, these data further confirm the enhancement of antitumor efficacy through combined endostatin and TRAIL gene therapy and provide a promising application prospect by virtue of adenovirus-mediated anti‑angiogenic and pro‑apoptotic cancer gene therapy.

View Figures

View References

1	Cha C, DeMatteo RP and Blumgart LH: Surgery and ablative therapy for hepatocellular carcinoma. J Clin Gastroenterol. 35(Suppl 2): S130–S137. 2002. View Article : Google Scholar : PubMed/NCBI
2	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar
3	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
4	Carr BI: Hepatocellular carcinoma: current management and future trends. Gastroenterology. 127:S218–S224. 2004. View Article : Google Scholar : PubMed/NCBI
5	Di Maio M, De Maio E, Perrone F, Pignata S and Daniele B: Hepatocellular carcinoma; systemic treatments. J Clin Gastroenterol. 35(Suppl 2): S109–S114. 2002.PubMed/NCBI
6	Prieto J, Qian C, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G, Mazzolini G, Sangro B and Kramer MG: Gene therapy of liver diseases. Expert Opin Biol Ther. 4:1073–1091. 2004. View Article : Google Scholar : PubMed/NCBI
7	Hernández-Alcoceba R, Sangro B and Prieto J: Gene therapy of liver cancer. Ann Hepatol. 6:5–14. 2007.
8	Cosman D: A family of ligands for TNF receptor superfamily. Stem Cells. 12:440–445. 1994. View Article : Google Scholar : PubMed/NCBI
9	Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
10	Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999. View Article : Google Scholar : PubMed/NCBI
11	Piras V, Hayashi K, Tomita M and Selvarajoo K: Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules. Sci Rep. 1:1442011. View Article : Google Scholar : PubMed/NCBI
12	Yang A, Wilson NS and Ashkenazi A: Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol. 22:837–844. 2010. View Article : Google Scholar : PubMed/NCBI
13	Nagane M, Huang HJ and Cavenee WK: The potential of TRAIL for cancer chemotherapy. Apoptosis. 6:191–197. 2001. View Article : Google Scholar : PubMed/NCBI
14	Yamaguchi N: An analysis of the functional mechanisms of endostatin-the anti-angiogenic activity of endostatin is mediated by its multiple binding ability. Connect Tissue. 36:171–178. 2004.
15	O’Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997.
16	Yamaguchi N, Anand-Apte B, Lee M, et al: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 18:4414–4423. 1999. View Article : Google Scholar : PubMed/NCBI
17	Bao Y, Feng WM, Tang CW, Zheng YY, Gong HB and Hou EG: Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization. Hepatogastroenterology. 59:1566–1568. 2012.PubMed/NCBI
18	Franceschi RT and Ge C: Gene delivery by adenoviruses. Methods Mol Biol. 455:137–147. 2008. View Article : Google Scholar : PubMed/NCBI
19	Lee J and Moon C: Current status of experimental therapeutics for head and neck cancer. Exp Biol Med. 236:375–389. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Qu ZH, Cui M, Guo C, Zhang XM, Ma CH and Sun WS: Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice. Cancer Biol Ther. 8:466–473. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wei YQ, Wang QR, Zhao X, et al: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 6:1160–1166. 2000. View Article : Google Scholar : PubMed/NCBI
22	Wei YQ, Huang MJ, Yang L, et al: Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA. 98:11545–11550. 2001. View Article : Google Scholar : PubMed/NCBI
23	Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H and Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature. 348:555–557. 1990. View Article : Google Scholar : PubMed/NCBI
24	O’Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315–328. 1994.PubMed/NCBI
25	Sauter BV, Martinet O, Zhang WJ, Mandeli J and Woo SL: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA. 97:4802–4807. 2000. View Article : Google Scholar : PubMed/NCBI
26	Lin T, Zhang L, Davis J, et al: Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther. 8:441–448. 2003. View Article : Google Scholar : PubMed/NCBI
27	Wissink EH, Verbrugge I, Vink SR, et al: TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. Radiother Oncol. 80:214–222. 2006. View Article : Google Scholar : PubMed/NCBI
28	Wu DS, Wu CM, Huang TH and Xie QD: Combined effects of radiotherapy and endostatin gene therapy in melanoma tumor model. Radiat Environ Biophys. 47:285–291. 2008. View Article : Google Scholar : PubMed/NCBI
29	Zhu LP, Xing J, Wang QX, et al: Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors. Eur J Pharmacol. 617:23–27. 2009. View Article : Google Scholar : PubMed/NCBI
30	Kim Y: The effects of nutrient depleted microenvironments and delta-like 1 homologue (DLK1) on apoptosis in neuroblastoma. Nutr Res Pract. 4:455–461. 2010. View Article : Google Scholar : PubMed/NCBI
31	Braun F, Bertin-Ciftci J, Gallouet AS, Millour J and Juin P: Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-xL inhibition. PLoS One. 6:e235772011. View Article : Google Scholar : PubMed/NCBI